Molecular mechanisms and clinical applications of angiogenesis

By Peter Carmeliet, Rakesh K. Jain. Nature, 2011

5,233 citations recorded by the source corpus.

Blood vessels deliver oxygen and nutrients to every part of the body, but also nourish diseases such as cancer. Over the past decade, our understanding of the molecular mechanisms of angiogenesis (blood vessel growth) has increased at an explosive rate and has led to the approval of anti-angiogenic drugs for cancer and eye diseases. So far, hundreds of thousands of patients have benefited from blockers of the angiogenic protein vascular endothelial growth factor, but limited efficacy and resistance remain outstanding problems. Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/cc1723f25e863386b91340ea03cd76a22de359ae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Vascular Endothelial Cell Biology: An Update (2019, background): “Activated VEGFR-2 recruits PI3-kinase and mediates the activation of a protein kinase B (Akt) and eNOS [46,53].”
The pathobiology of vascular dementia (2013, positive): “In the developing nervous system, prototypical neural guidance signals, ephrins, netrins, slit glycoproteins, and semaphorins also contribute to endothelial tip cell guidance (Carmeliet and Jain, 2011).”
ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, neutral): “, HIFs/VEGF, and Ang2) (Carmeliet and Jain, 2011); resistance to apoptosis/autophagy (e.”
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors (2012, background): “Finally, hypoxia lowers the efficacy of radiation, chemotherapy, and immunotherapy (22, 55).”
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. (2013, background): “Pathologies characterized by abnormal vessels afflict more than a half billion people worldwide.(4,16) These include wet age-related macular degeneration and diabetic macular edema—leading causes of blindness.”
Basic and therapeutic aspects of angiogenesis. (2011, positive): “Recent studies provided tremendous insights into fundamental aspects of angiogenesis that have led to amechanistic model of vessel branching (Adams and Alitalo, 2007; Carmeliet and Jain, 2011; Eilken and Adams, 2010; Phng and Gerhardt, 2009).”
The role of mechanical forces in tumor growth and therapy (2014, neutral): “Furthermore, a hypoxic microenvironment can select for cells that can survive in a harsh microenvironment, which enhances the invasive and metastatic potential of cancer cells and lowers the efficacy of radiation and immunotherapy (1, 43-45).”
Role of Matrix Metalloproteinases in Angiogenesis and Cancer (2019, background): “a cytokine VEGF homolog that stimulates angiogenesis and various types of cells, such as myeloids and stromals cancers, in addition to activating tumor cells, while their inhibition improves cancer treatment (33).”
PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “VEGF is a growth factor that regulates blood and lymphatic vessel development (by signaling vascular endothelial cells to undergo proliferation, migration and differentiation into new blood vessels) and it also presents some effects on neural cells [175,176].”